Algernon Health Inc. (CSE:AGN)
Canada
· Delayed Price · Currency is CAD | Market Cap | 1.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.93M |
| Shares Out | 47.28M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,777 |
| Average Volume | 73,854 |
| Open | 0.0400 |
| Previous Close | 0.0400 |
| Day's Range | 0.0400 - 0.0400 |
| 52-Week Range | 0.0400 - 0.1000 |
| Beta | 1.25 |
| RSI | 19.72 |
| Earnings Date | Feb 4, 2026 |
About Algernon Health
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in Oc... [Read more]
Financial Performance
Financial StatementsNews
Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon...
Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon...
Algernon Closes Second Tranche of Private Placement Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon...
Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon...
Algernon Closes First Tranche of its Recently Announced Private Placement Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon...
Algernon Health Announces Private Placement
VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased...
CSE Bulletin: Name Change - Algernon Pharmaceuticals Inc. (AGN)
Toronto, Ontario--(Newsfile Corp. - Le 16 octobre/October 2025) - Algernon Pharmaceuticals Inc. has announced a name change to Algernon Health Inc. Shares will begin trading under the new name and wit...
Algernon Pharmaceuticals Completes Name Change to Algernon Health
VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company an...
Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals
PITTSBURGH , Oct. 7, 2025 /PRNewswire/ -- Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with ...
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...
Algernon Pharmaceuticals Announces Name Change to Algernon Health
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...
Algernon Announces Closing of the Private Placement Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Algernon Announces $1M Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “...
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...
Algernon Announces Warrant Extension
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pha...
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...
Algernon Pharmaceuticals Announces Closing of Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...
Algernon Pharmaceuticals Announces Increase to Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...
Algernon Pharmaceuticals Announces Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...